Tag Archives | HCV

Biotech Bull Market Rolls On in a Volatile Q2 2015: XBI Up 12.4%

Dealmaking and Fast Money Fuel Biotechs Q2 2015 Review Despite a major down trend at the end of April and the recent sell-off, the sector outperformed in Q2 of 2015. The S&P was down 1% and flat YTD. The XBI¬†Biotech ETF continues to be the sector ETF leader up 12.41% compared to 5% for the […]

Continue Reading 0

Regulatory News for Rare Disease Products-Hot Stocks: BLUE,ICPT,SRPT …Updates

Update-2 uniQure up on deal with BMY (CURE) Cardiovascular Deal with Bristol Myers (BMY) The closing of the uniQure deal with Bristol Myers triggered a $50M payment. Three collaboration targets in cardiovascular and future areas. The stock is up 81% YTD but off its high of $35.50. Update-1 See Chart below of Emerging Orphan drug […]

Continue Reading 0

Biotechs Tag Along With Broad Market Rally: FBT Up 3%

Jobs Report Drive Stocks Higher-DOW Up 1.5% Stocks moved higher on the “goldilocks” job report which showed a gain of 223k added in April. The jobs number was too high to raise concerns about an increase in rates but not too bullish because overall productivity is down. Jobless claims are down also tracking an improved […]

Continue Reading 0

Surveying the Damage with Rayno Life Science Stocks…2015 YTD

Biotech Bounce-Caution on New Positions IBB up 2% at 340 support level Most biotech stocks are green as of early trading on May 1. Although the sector has taken a beating since April 23 most ETFs and funds are outperforming the market year to date up more than 10%. As we posted earlier this week […]

Continue Reading 0

Biotech Buzz Is Broken…Update 4/30…#2

Gilead (GILD) Gilead Beats Q1 Estimates: $7.4B Sales HCV , EPS $2.94, stock up 2% after hours XBI Down Another 4% Down 12.84% in Five Days Weak Tape and Sell-Off Continues…4/30…NASDAQ at 4991 XBI down 1.6% now at 2/24 lows at 212 High fliers hit with profit taking…ADRO, AGIO, JUNO, KITE etc. Large cap Celgene […]

Continue Reading 0